Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Imfinzi: Global Drug Analysis (2017) with Forecasts to 2026 - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Imfinzi" drug pipelines has been added to ResearchAndMarkets.com's offering.

AstraZeneca's Imfinzi is a human monoclonal antibody targeting PD-L1. Programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell-surface molecules and the CTLA-4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology. The pathways have a similar effect on T-cell immune response but are distinct from each other (Keir et al., 2008).

Key Topics Covered:

Product Profiles

  • Imfinzi: Head and neck cancer
  • Imfinzi: Bladder cancer
  • Durvalumab: Non-small cell lung cancer (NSCLC)

List of Figures

Figure 1: Imfinzi for head and neck cancer - SWOT analysis

Figure 2: Drug assessment summary of Imfinzi for SCCHN

Figure 3: Drug assessment summary of Imfinzi for SCCHN

Figure 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Imfinzi for urothelial bladder cancer - SWOT analysis

Figure 6: Drug assessment summary for Imfinzi in urothelial bladder cancer

Figure 7: Drug assessment summary for Imfinzi in urothelial bladder cancer

Figure 8: Durvalumab for non-small cell lung cancer - SWOT analysis

Figure 9: Drug assessment summary for durvalumab in non-small cell lung cancer

List of Tables

Table 1: Imfinzi drug profile

Table 2: Imfinzi Phase III trials in head and neck cancer

Table 3: Imfinzi early-phase data in head and neck cancer

Table 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 5: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

Table 6: Imfinzi drug profile

Table 7: Imfinzi pivotal trial data in urothelial bladder cancer

Table 8: Imfinzi ongoing late-phase trials in urothelial bladder cancer

Table 9: Durvalumab drug profile

Table 10: Durvalumab Phase III trials in non-small cell lung cancer

Table 11: Durvalumab early-phase data in non-small cell lung cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gb8pm2/imfinzi_global?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005680/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.